BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 17652581)

  • 21. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
    Fan MM; Fernandes HB; Zhang LY; Hayden MR; Raymond LA
    J Neurosci; 2007 Apr; 27(14):3768-79. PubMed ID: 17409241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.
    Wu J; Ryskamp D; Birnbaumer L; Bezprozvanny I
    J Huntingtons Dis; 2018; 7(1):35-50. PubMed ID: 29480205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential electrophysiological changes in striatal output neurons in Huntington's disease.
    André VM; Cepeda C; Fisher YE; Huynh M; Bardakjian N; Singh S; Yang XW; Levine MS
    J Neurosci; 2011 Jan; 31(4):1170-82. PubMed ID: 21273402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
    Ebert AD; Barber AE; Heins BM; Svendsen CN
    Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
    Bezprozvanny I
    Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An automated and quantitative method to evaluate progression of striatal pathology in Huntington's disease transgenic mice.
    Liang X; Wu J; Egorova P; Bezprozvanny I
    J Huntingtons Dis; 2014; 3(4):343-350. PubMed ID: 25575955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.
    Sepers MD; Raymond LA
    Drug Discov Today; 2014 Jul; 19(7):990-6. PubMed ID: 24603212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striatal neurochemical changes in transgenic models of Huntington's disease.
    Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
    J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
    Kolodziejczyk K; Raymond LA
    Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
    Xie Y; Hayden MR; Xu B
    J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.
    Ruiz-Calvo A; Maroto IB; Bajo-Grañeras R; Chiarlone A; Gaudioso Á; Ferrero JJ; Resel E; Sánchez-Prieto J; Rodríguez-Navarro JA; Marsicano G; Galve-Roperh I; Bellocchio L; Guzmán M
    Cereb Cortex; 2018 Jan; 28(1):307-322. PubMed ID: 29121220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.
    Park KH; Lu G; Fan J; Raymond LA; Leavitt BR
    J Huntingtons Dis; 2012; 1(1):89-96. PubMed ID: 24353748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
    Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
    Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential changes to D1 and D2 medium spiny neurons in the 12-month-old Q175+/- mouse model of Huntington's Disease.
    Goodliffe JW; Song H; Rubakovic A; Chang W; Medalla M; Weaver CM; Luebke JI
    PLoS One; 2018; 13(8):e0200626. PubMed ID: 30118496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
    Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
    J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations.
    Malaiya S; Cortes-Gutierrez M; Herb BR; Coffey SR; Legg SRW; Cantle JP; Colantuoni C; Carroll JB; Ament SA
    J Neurosci; 2021 Jun; 41(25):5534-5552. PubMed ID: 34011527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.